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Diseased Skeletal Muscle
A Noncardiac Source of Increased
Circulating Concentrations of Cardiac Troponin T
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Amy K. Saenger, PHD,* Kalen N. Olson, PHD,§ Fred S. Apple, PHD§
Rochester and Minneapolis, Minnesota
Objectives The purpose of this study was to determine whether there is immunoreactive cardiac troponin T (cTnT) expres-
sion in diseased skeletal muscle that might cause possible false-positive increases in cTnT.
Background Cardiac troponin (I or T) is the biomarker of choice for the diagnosis of cardiac injury. Recently, we were pre-
sented with a case that challenged the specificity of cTnT.
Methods Patients with myopathies seen in the Neuromuscular Clinic at the Mayo Clinic were screened for increases in
cTnT. If present, an assay for cTnI was performed. If normal, skeletal biopsy tissue was obtained for Western
blot analysis using the capture and detection antibodies from both the fourth-generation and high-sensitivity
cTnT assays. Results were compared with findings in normal cardiac tissue.
Results Sixteen patients had increases in cTnT but not cTnI. All had a myopathy by clinical evaluation, clinical testing,
and biopsy. Four residual biopsy samples were obtained. All 3 antibodies used in the cTnT (M11.7, M7) and high-
sensitivity cTnT (5D8, M7) assays were immunoreactive with a 37- to 39-kDa protein in all 4 diseased skeletal
muscle biopsy specimens and in cardiac tissue. A second immunoreactive isoform (34 to 36 kDa) was also
found in 1 patient. None of the noncardiac control tissues expressed immunoreactive protein.
Conclusions These results document that there are forms in diseased skeletal muscle that could cause increases in circulat-
ing levels of cTnT. These increases could reflect re-expressed isoforms. Clinicians need to be aware of the possi-
bility that noncardiac increases in cTnT may occur and lead to a possible false-positive diagnosis of cardiac in-
jury when skeletal muscle pathology is present. (J Am Coll Cardiol 2011;58:1819–24) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.026Both cardiac troponin T (cTnT) and cardiac troponin I
(cTnI) are the biomarkers of choice for the evaluation of
patients with possible cardiac injury, largely because of their
unique tissue specificity (1,2). The specificity of the first-
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accepted August 16, 2011.generation cTnT assay (Roche Diagnostics, Indianapolis,
Indiana) was questioned initially when increased concentra-
tions of cTnT were found in patients with renal failure and
skeletal muscle diseases (3,4). Subsequent studies docu-
mented a lack of specificity of the capture antibody in the
first-generation assay, which detected both cardiac isoforms
and some fetal skeletal muscle cTnT isoforms re-expressed
in skeletal muscle in response to injury (3–5). These
re-expressed fetal isoforms were characterized, and a new
antibody was developed by Roche Diagnostics and validated
not to detect these re-expressed skeletal muscle cTnT
isoforms (6–9). This was confirmed predominantly, but not
exclusively, in patients with end-stage renal disease in 2
series of extensive experiments conducted by different
groups that ultimately resulted in the conclusion that cTnT
had unique cardiac specificity that was equal to that of cTnI
(1,2). Our continued interest in the specificity of the cTnT
assay was stimulated in May 2007 by interactions with
a senior clinician at the Mayo Clinic (Rochester,
Minnesota).
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evaluated a 46-year-old gentle-
man who presented to the emer-
gency department with a history
of atypical chest discomfort. His
electrocardiogram had been un-
remarkable and his story atypical,
but serial cTnT concentrations
were modestly increased (0.12
g/l and 0.09 g/l, 99th percen-
tile  0.01 g/l) and remained
increased without an increasing
and/or decreasing pattern. Crea-
tine kinase-myocardial band
(CK-MB) was also increased (26.8 g/l, upper limit of
normal  6.2 g/l) as was total CK at 758 IU/l (upper
eference range for age/sex  366 IU/l) and aldolase at 11.4
/l (upper reference range 7.7 U/l). A comprehensive
hysical examination was unremarkable. Chest x-ray,
ardiac magnetic resonance imaging, and coronary an-
iography findings were normal except for mild left
entricular hypertrophy. There was no evidence of a
alse-positive result as samples diluted linearly, and cTnT
oncentrations were not altered after treatment with
eterophilic antibody blocking. cTnI was measured on
he Stratus CS instrument (Siemens, Newark, Delaware)
nd was normal, just above the level of detection of that
ssay. Although a myopathy was not clinically apparent,
ased on the elevated muscle enzymes, the patient was
eferred to the Neuromuscular Clinic. At that time, a
linical diagnosis of a proximal myopathy predominantly
nvolving the shoulder girdle muscles was made. Electro-
yography showed proximal myopathic changes with
brillation potentials. A muscle biopsy of the right
riceps was performed and showed signs of an active and
hronic myopathy without specific structural changes,
ompatible with muscular dystrophy, and a few collec-
ions of inflammatory cells at perivascular sites in the
erimysium (Fig. 1). Sequencing of caveolin 3; calpain 3;
ysferlin; fukutin-related protein; alpha-, beta-, gamma-,
nd delta-sarcoglycans; and dystrophin detected no mu-
ations, and genetic testing for facioscapulohumeral mus-
ular dystrophy (FSHD) revealed no deletion. A trial of
rednisone was initiated with no objective improvement
n strength. Subsequent genetic testing for FSHD with
nalysis of alleles 4qA and 4qB confirmed the diagnosis
f FSHD.
After this episode, a protocol was developed to accumu-
ate skeletal muscle biopsy tissue from patients seen in the
euromuscular Clinic by the neurologist involved (M.M.) if
hey had increased cTnT concentrations but normal cTnI
alues. Our protocol was designed to allow us to use the
issue left over after skeletal muscle biopsy for subsequent
iochemical evaluation. Our hypothesis was that increases
n cTnT might be due to the diseased skeletal muscle
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
cTnI  cardiac troponin I
cTnT  cardiac troponin T
FSHD  facioscapulohumeral
muscular dystrophy
MAb  monoclonal
antibody
TBS-T  Tris-buffered saline
Tweenreviously undetected. tethods
rom 2007 to 2009, one of the coauthors (M.M.) who
valuates patients in the Neuromuscular Clinic identified
atients with possible increased cTnT values. In these
atients, both cTnT and cTnI was measured. Patients all
ad a general history taken and a physical examination, a
otal CK measurement, and electromyography performed.
hey also usually underwent electrocardiography and echo-
ardiography because many myopathies can have cardiac
nvolvement. Only patients who either had recently under-
one a biopsy or in whom one was anticipated were
ncluded. Those returning for follow-up visits, those with
omplex disease, and those with overt cardiovascular abnor-
alities were excluded. We obtained informed consent to
se patients’ biopsy and clinical data in the group with
levated cTnT but normal cTnI only after a skeletal biopsy
f the abnormal skeletal muscle was performed for diagnos-
Figure 1 Muscle Biopsy of the Triceps in the Index Patient
Hematoxylin and eosin–stained sections show muscle fiber size variability,
increase in internal nuclei, fiber splitting, regenerating fibers, increased
endomysial connective tissue (A) and perivascular inflammatory exudate in a
perymisial region (B). Bars  200 m (A), 100 m (B).ic purposes.
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October 18, 2011:1819–24 Elevated cTnT Due to Skeletal Muscle DiseasecTnT was quantitated with the fourth-generation cTnT
assay on the Elecsys E170 analyzer (Roche Diagnostics).
The assay has a coefficient of variation of 10% at 0.035 g/l
and the 99th percentile concentration used to define abnor-
mality is 0.01 g/l (6). The high-sensitivity assay for cTnT
s not approved in the United States and was not used in
hese patients. cTnI was measured on the Stratus CS
nalyzer (Siemens). The 99th percentile concentration for
his assay is 0.07 g/l and the 10% coefficient of variation
oncentration is 0.1 g/l (10). All assays were performed in
he Central Clinical Laboratory or the Cardiovascular Lab-
ratory at the Mayo Clinic.
TnT Western blot. Dr. Apple’s laboratory at the Min-
eapolis Medical Research Foundation of the Hennepin
ounty Medical Center was used to analyze the biopsy
amples because of their experience in this area in studies
one some years ago when the issue of cross-reactivity of the
TnT assay with skeletal muscle from patients with renal
ailure was raised (8,9). As previously described (8), diseased
keletal muscle (n  4), nondiseased psoas skeletal muscle
n  2), and normal heart muscle tissue specimens (n  2)
ere obtained from the Hennepin County Medical Exam-
ner’s office. The nondisease skeletal and cardiac tissue were
btained from young patients who died of a drug overdose.
amples were placed in a mortar cooled on dry ice. Liquid
itrogen was added, and the tissue was coarsely ground and
hen transferred into a glass dounce tissue grinder. The
issue was ground in extraction buffer (200 mmol/l potas-
ium phosphate, pH 7.4, 5 mmol/l ethyleneglycol tetraacetic
cid, 5 mmol/l -mercaptoethanol, and 100 ml/l glycerol)
to release both mitochondrial and cytoplasmic proteins. The
samples were then stored in microtubes at 80°C until
analysis. The total protein contained in each tissue extrac-
tion sample was estimated following the manufacturer’s
instructions for the BCA Protein Assay Kit (Thermo
Scientific Pierce, Rockford, Illinois).
The monoclonal capture and detection cTnT antibodies
(M7 detection antibody for both fourth-generation and
high-sensitivity assays; M11.7 capture antibody for fourth-
generation assay; 5D8 capture antibody for high sensitivity
assay) used in the Roche cTnT diagnostic immunoassays
were provided by Roche Diagnostics GmbH (Dr. Klaus
Hallermayer). M7 recognizes residues 125 to 131. 5D8 is a
chimeric antibody derived from M11.7. Both recognize
residues 136 to 147 of the cTnT protein sequence. Immu-
nopure goat anti-mouse IgG horseradish peroxidase–
conjugated secondary antibody was obtained from Thermo
Scientific Pierce.
Protein extracts (53 to 84 g) in sample buffer were
ize-fractionated by sodium dodecylsulfate polyacrylamide
lectrophoresis on precast 10% Precise Protein Gels
Thermo Scientific Pierce) using the Mini-Protean 3 system
Bio-Rad Laboratories, Hercules, California). Proteins were
hen transferred to Hybond ECL nitrocellulose membrane
GE Healthcare, Piscataway, New Jersey) at 90 V for 1 h at
°C in transfer buffer (0.025 M Tris, 0.18 M glycine, 15%ol/vol methanol). The membrane was then treated in 1 of
ways. First, membranes were blocked for 1 h at room
emperature in blocking buffer containing nonfat dry milk
50 g/l) in Tris-buffered saline Tween (TBS-T) (1 M Tris,
H 7.5, 4 M NaCl, 0.1% Tween-20). The membranes were
ubsequently incubated overnight at 4°C on a rotator in
rimary antibody (1 g/ml) diluted in antibody buffer (10
/l nonfat dry milk in TBS-T). The following day, the
embranes were washed 3 times for 10 min each in TBS-T
efore incubation for 1 h at room temperature in secondary
ntibody (80 g/l) diluted with TBS-T. The membranes
were again washed in TBS-T 3 times for 10 min each, then
incubated for 1 min with electrochemiluminescent substrate
(GE Healthcare). The signal was captured using a Kodak
Image Station (Rochester, New York) and associated im-
aging software. For the cTnT antigen-blocking experiment,
the same protocol was used, but in addition, 20 g of
ecombinant cTnT was incubated with the primary anti-
ody solution for 15 min before overnight incubation.
lternatively, after electrophoresis and transferring, the
embranes were used with a Fast Western Blot Kit (Su-
ersignal West Dura, Thermo Scientific Pierce). Briefly, the
embranes were washed once briefly with 1 Fast wash
uffer before incubation with primary antibody (1 g/ml)
diluted in antibody diluent (provided in kit) for 35 min at
room temperature. In a new tray, the membranes were
incubated with the kit horseradish peroxidase reagent at
room temperature for 15 min. Subsequently, the mem-
branes were placed in a clean tray and washed in 1 Fast
wash buffer 3 times for 5 min each before incubation with
Dura ECL substrate for 5 min and imaging on the Kodak
Image Station.
Results
No attempt was made to comprehensively screen clinic
patients for this study. Eighteen patients were identified for
study. One patient had myophosphorylase deficiency
(McArdle’s disease) and a normal cTnT value. The other 17
had an increased cTnT values, and 1 had a concomitant
increase in cTnI. This patient had a cardiomyopathy not
originally diagnosed accompanying a vacuolar myopathy.
One patient with genetically proven FSHD and 1 other did
not have a biopsy done. Of the remaining 14, consent to use
their clinical data and residual biopsy specimen could be
obtained from only 7 patients. However, there were 3
patients whose biopsies had been done outside of Mayo, and
their tissue samples could not be retrieved. Therefore, a total
of 4 biopsy samples were used in the Western blot analyses.
Clinical data for the 7 patients from the Neuromuscular
Clinic who signed informed consent and had increased
concentrations of cTnT and normal or undetectable cTnI
are shown in Table 1. All patients who underwent biopsies
had a myopathy, as suggested by clinical history, examina-
tion, CK increases (range 583 to 3,500 IU/l), and myopathic
electromyographic and histologic changes. The patients
HTN 
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quently with immunotherapy. The first 4 patients listed in
Table 1 had muscle biopsy tissue available for Western blot
analysis. All these patients had normal electrocardiogram
findings, all but 1 had totally normal echocardiogram
findings, and 1 had a negative exercise sestamibi scan. None
of the patients had a history of or findings suggestive of
cardiovascular disease.
Representative Western blots of nondiseased human
heart muscle (lane 5), nondiseased skeletal muscle (lane 6),
and skeletal muscle from patients with myopathies (lanes 1
through 4) using monoclonal antibodies (MAbs) M7,
M11.7, and 5D8 are illustrated in Figure 2. In nondiseased
human heart muscle, the major immunoreactive protein was
detected at approximately 37 to 39 kDa with all 3 antibod-
ies. This protein appeared similar in molecular weight to the
primary immunoreactive protein found in all 4 diseased
skeletal muscle biopsy samples with all 3 MAbs. This
protein was more strongly detected with the 5D8 and
M11.7 MAbs compared with M7 MAb. Because there was
a slight bowing in the gel, a curvature makes it appear that
it is possible that a different immunoreactive species at a
Characteristics of the Muscle-Diseased PatientsTable 1 Characteristics of the Muscle-Disea
Patient # Diagnosis cT
1 FHSD
2 Inflammatory
3 Necrotizing/immunomediated
4 IBM
5 IBM
6 Necrotizing/immunomediated
7 IBM
The samples from Patients #1 to #4 were used in the Western blot st
Bifascicular block  right bundle branch block with anterior fascic
diabetes mellitus; FHSD  facioscapulohumeral muscular dystrophy;
large granular lymphocytosis.
Figure 2 Western Immunoblots
Skeletal muscle from patients with skeletal muscle disease (SMD) (lanes 1
through 4), nondiseased human heart muscle (NHHM) (lane 5), nondiseased
human skeletal muscle (NHSM) (lane 6), all probed with cardiac troponin T
monoclonal antibodies M7, 5D8, or M11.7. The asterisks indicate the region
of the protein of interest.slightly higher molecular weight may have been detected in
the diseased skeletal muscle compared with the nondiseased
heart. An additional strong immunoreactive band appeared
in 1 diseased skeletal muscle patient with the M11.7 MAb,
corresponding to a molecular weight of approximately 34 to
36 kDa (lane 3 in Fig. 2), and faintly in another patient
(lane 4) with M11.7. This band also appeared faintly in the
same patients with use of 5D8 MAb. No bands were
apparent in nondiseased human skeletal muscles for any of
the MAbs. The protein concentration was not equalized
across samples. Therefore, assumptions regarding relative
abundance of protein isoforms cannot be made. A negative
control experiment, intended to block binding of the anti-
bodies to the cTnT on the blot membrane through pre-
incubation of the M7, M11.7, or 5D8 with cTnT antigen
(provided by Roche Diagnostics), resulted in none of the
bands appearing in any sample (Fig. 3). Both capture M11.7
Patients
g/l)* cTnI (g/l)* Comorbidities
.12 0.03 HTN, Chol, atypical CP
.19 0.03 Arthritis
0.04 History of lymphomas
0.03 LGL leukemia
.40 0.03 DM, HTN, Chol
0.03 Psoriasis
0.05 DM, bifascicular block
Serum concentrations.
ck; Chol  elevated cholesterol by history; CP  chest pain; DM 
hypertension; IBM  inclusion body myositis; LGL leukemia  T-cell
Figure 3 Western Immunoblots of Skeletal Muscle From
Patients 1 Through 4 With Skeletal Muscle Disease
In the top panel, the M7 antibody is blocked with cardiac troponin T (cTnT)
antigen, and just below that, it is not. In the third panel, the M11.7 antibody is
blocked with cTnT antigen, and in the bottom panel, it is not. There are 2
lanes labeled heart, and one as normal soleus muscle. The asterisk indicates
the region of the protein of interest. I  molecular weight standards.sed
nT (
0.11–0
0.16–0
0.47
0.07
0.36–0
0.18
0.23
udies. *
ular blo
p
a
c
d
H
e
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October 18, 2011:1819–24 Elevated cTnT Due to Skeletal Muscle Diseaseand 5D8 MAbs and the detection MAb M7 demonstrated
immunoreactivity with the same molecular weight proteins
in diseased skeletal muscles and in the heart.
Discussion
These data provide evidence that increased concentrations
of cTnT detected in patients with skeletal muscle disease
could be derived from diseased skeletal muscle. The West-
ern blot evidence from the patients examined indicates that
there are proteins expressed in diseased skeletal muscle that
are detected by the antibodies used in both the fourth-
generation and high-sensitivity cTnT assays. In theory,
these could be different proteins despite a similar molecular
weight. It is more likely that the increased cTnT in these
patients, which coincided with normal cTnI concentrations,
was released from the diseased skeletal muscle and not from
cardiovascular involvement. However, even in the patient
extensively evaluated as our index patient who had a
myopathy (FSHD) not known to involve the heart, we
cannot say with absolute certainty that he did not have
cardiac involvement below our ability to detect it with
conventional measures. Patients with left ventricular hyper-
trophy have been shown to manifest in elevations of cTnT
(11). It also is known that skeletal muscle myopathies can
involve the myocardium. This is also the case for the other
patients as well who were less extensively evaluated. How-
ever, it is likely that release of the immunoreactive forms
that we have described in diseased skeletal muscle were
responsible for the increases in cTnT detected in these
patients.
The immunodetection of cTnT isoforms in skeletal
muscle obtained at biopsy from various pathologies has been
previously explored (8,9). Perhaps had we probed other
etiologies for skeletal muscle disease more extensively in our
initial studies or used the methods with increased detection
sensitivity that we now use, we would have detected earlier
the problem we now describe. However, the previous work
from our lab using both the M11.7 and M7 antibodies for
blotting chronic renal disease skeletal muscle was unable to
detect similar molecular weight bands within the same
skeletal muscles for both antibodies as described in the
current study. In the renal disease model, M11.7 detected
immunoreactivity between 34 and 36 kDa. Similar immu-
noreactivity was also found in the current study in 2 of the
diseased skeletal muscles, along with immunoreactivity at 37
to 39 kDa that was not observed previously. Further,
findings for M7, with detection of immunoreactivity at
approximately 39 kDa in the current study, were similar to
the 39-kDa immunoreactivity found in the renal disease
model. Without extraction of the immunoreactive bands
and sequencing their amino acid compositions, we cannot
conclusively prove that the epitopes being detected by the 3
MAbs used by Roche Diagnostics are identical between the
heart and diseased skeletal muscles. Thus, we cannot say
definitively that what was detected in skeletal muscle were cre-expressed cTnT isoforms. Further biochemical studies
are needed to better define the science.
The critical questions with regard to these data are:
1) what is the prevalence of cTnT increases due to skeletal
muscle disease; and 2) what is the extent to which these
increases may confound detection of patients with true
cardiovascular disease. Our data do not directly address this
important issue. We did not systematically evaluate the
frequency of such increases in our Neuromuscular Clinic but
focused instead on exploring a biochemical proof-of-
concept study based on biopsies and Western blot analysis.
We found 16 patients with discrepancies between cTnT and
cTnI. We know that 4 had the biochemical profile in their
skeletal muscle to explain those findings. We cannot be
100% definitive even in our index case that the increased
cTnT concentrations were not due to concurrent cardiac
disease. However, it appears likely that there are at least
some circumstances in which increases appear to be due to
noncardiac sources of cTnT, and these certainly could lead
to confusion in individual clinical cases.
There are 2 studies that have been published that partially
address this issue. They suggest that patients who have
myopathies can have increases in cTnT and CK-MB
concomitantly but not in cTnI, and changes in these
elevated values appear to be more related to activity of the
underlying skeletal muscle disease than cardiovascular ab-
normalities (12,13). Unfortunately, in these studies, a vari-
ety of cTnI immunoassays with varying sensitivities were
used, and there was no direct evidence of skeletal muscle
cTnT expression. Our study thus is a critical proof-of-
concept study because it is the first to include biochemical
proof of this hypothesis using the antibodies used commer-
cially in the assay. Nonetheless, the reports cited here
include nearly 100 patients (12,13) with increases in cTnT
that correlate with increases in CK-MB but not with cTnI,
suggesting that the frequency of such clinically undetected
myopathies may not be trivial. In addition, the myopathies
involved such as inclusion body myopathy and FSHD
themselves are not rare (14–16). Regardless of the frequency
of increases of cTnT due to skeletal muscle involvement
with the present iteration of the cTnT assay, the high-
sensitivity cTnT may detect a substantially greater number
of such increases.
It is unlikely that these increases in cTnT are ubiquitous.
If that were the case, the frequency of cTnT increases
recently reported using the high-sensitivity cTnT assay by
de Lemos et al. (11) would have been much higher than the
2% who were reported to have concentrations 99th
ercentile value and only 0.06% did not have a cardiac
bnormality. Similarly, the very robust prognostic signifi-
ance of these high-sensitivity cTnT increases would be
ifficult to document if such increases were very frequent.
owever, even if the frequency of false-positive increases is
xtremely low, given the large numbers of patients evaluated
ith this testing (17), the absolute numbers of patients whoould have increases due to skeletal muscle disease could be
1824 Jaffe et al. JACC Vol. 58, No. 17, 2011
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question until better data are available. Nonetheless, clini-
cians need to be aware of this problem and consider it in
patients with increases in cTnT that do not seem appropri-
ate for the clinical situation.
There are no data available to suggest that these isolated
increases that could be due to skeletal muscle injury should
affect the diagnosis of acute myocardial infarction, which
should be based on an increasing and/or decreasing pattern
of cTnT values in the appropriate clinical circumstance
because in the 3 patients for whom multiple samples were
available, changes over time were small. However, if clini-
cians only rely on the presence of an increased value or if the
timing of the patient’s presentation precludes evaluation for
an increasing and/or decreasing pattern, these increases
could cause confusion. One also could ensure the tissue
specificity of the cTnT concentration by measuring cTnI
with a sensitive, contemporary assay to confirm or refute the
increase, as was done with our study, because detection of
cTnI in skeletal muscle has not been observed despite many
studies using techniques similar to the ones that we used
(18,19). This may not be practical in many settings.
Study limitations. We did not and cannot determine the
frequency of elevations in cTnT due to skeletal muscle. In
addition, characterization of the protein or proteins respon-
sible for the signal we detected has not been accomplished
as yet. However, such identification is not essential for the
phenomenon we have described. Additional studies are
clearly needed.
Conclusions
Our skeletal muscle tissue findings provide a rationale for
the findings of at least 2 clinical studies (12,13) suggesting
that the phenomenon of cTnT increases in the absence of
cardiovascular disease can occur. Our results suggest that the
unique specificity thought to occur for both cTnT and cTnI
may no longer be sustained for the cTnT assay in its current
formulation. Clinicians need to keep this in mind when
evaluating patients for potential cardiovascular disease who
may have an underlying skeletal myopathy, albeit subtle,
especially when their clinical presentations are atypical and
where increases of cTnT seem to stand alone in indicating
cardiovascular involvement.
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